SCHEMBL11909403

SCHEMBL11909403

CC(=O)N1CC(n2cc(Br)cn2)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 2/20 0.48
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
TYK2 P29597 1/20 0.40
JAK3 P52333 1/20 0.40
KDM4A O75164 2/20 0.40
KDM5C P41229 2/20 0.40
KDM4C Q9H3R0 2/20 0.40
KDM3A Q9Y4C1 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ELANE P08246 3/20 0.39
PLAU P00749 2/20 0.39
F2 P00734 1/20 0.39
KLKB1 P03952 1/20 0.39
MAP4K1 Q92918 1/20 0.36
CHRNB2 P17787 2/20 0.34
CHRNA3 P32297 2/20 0.34
CHRNA4 P43681 2/20 0.34
CHRNB3 Q05901 1/20 0.34
CHRNA6 Q15825 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20519554 0.89 KDM5A (0.60) KDM5AJAK1TYK2JAK3KDM4A
SCHEMBL17240133 0.85 KDM5A (0.46) KDM5AKDM4AKDM5CKDM4CKDM3A
SCHEMBL20757579 0.85 KDM4E (0.40) KDM5AJAK2JAK1TYK2JAK3
SCHEMBL1582361 0.84 KDM5A (0.52) KDM5AJAK1TYK2JAK3MAP4K1
SCHEMBL29666008 0.83 KDM5A (0.46) KDM5AJAK2JAK1TYK2JAK3
SCHEMBL3598372 0.80 KDM5A (0.43) KDM5AELANE
SCHEMBL13574170 0.78 KDM5A (0.39) KDM5AELANEPLAUF2KLKB1
SCHEMBL22118591 0.77 KDM5A (0.57) KDM5AKDM5CKDM4CKDM3AELANE
SCHEMBL22118628 0.77 KDM5A (0.57) KDM5AKDM5CKDM4CKDM3AELANE
SCHEMBL14862909 0.77 KDM5A (0.57) KDM5AKDM5CKDM4CKDM3AELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3601284-B1 NAPHTHYRIDINES AS INHIBITORS OF HPK1 HOFFMANN LA ROCHE (CH) 2023-12-27 EP disclosed
CN-110678466-B Diazanaphthalenes as HPK1 inhibitors 豪夫迈·罗氏有限公司 2023-01-31 CN disclosed
US-11034692-B1 Naphthyridines as inhibitors of HPK1 GENENTECH, INC. (US) 2021-06-15 US disclosed
US-11034692-B1 Naphthyridines as inhibitors of HPK1 GENENTECH, INC. (US) 2021-06-15 US disclosed
CN-110678466-A Naphthyridines as HPK1 inhibitors 豪夫迈·罗氏有限公司 2020-01-10 CN disclosed
US-10407424-B2 Naphthyridines as inhibitors of HPK1 GENENTECH, INC. (US) 2019-09-10 US disclosed
US-10407424-B2 Naphthyridines as inhibitors of HPK1 GENENTECH, INC. (US) 2019-09-10 US disclosed
EP-2300465-B1 IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES ASTEX THERAPEUTICS LTD (GB) 2019-04-17 EP disclosed
EP-2300465-B1 IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES ASTEX THERAPEUTICS LTD (GB) 2019-04-17 EP disclosed
US-20180282328-A1 NAPHTHYRIDINES AS INHIBITORS OF HPK1 GENENTECH, INC. (US) 2018-10-04 US disclosed
US-8796244-B2 Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases ASTEX THERAPEUTICS LTD (GB) 2014-08-05 US disclosed
US-8796244-B2 Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases ASTEX THERAPEUTICS LTD (GB) 2014-08-05 US disclosed
US-8796244-B2 Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases ASTEX THERAPEUTICS LTD (GB) 2014-08-05 US disclosed
US-20120208791-A1 IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES ASTEX THERAPEUTICS LIMITED (GB) 2012-08-16 US disclosed
US-20120208791-A1 IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES ASTEX THERAPEUTICS LIMITED (GB) 2012-08-16 US disclosed
US-20120208791-A1 IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES ASTEX THERAPEUTICS LIMITED (GB) 2012-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10407424-B2 Naphthyridines as inhibitors of HPK1 NEK1, NEK5, NEK11 KDM5A 3056/4885JAK2 4501/4885JAK1 4271/4885
US-20120208791-A1 IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES ABL1, ERBB2, RET KDM5A 1546/4885JAK2 7/4885JAK1 21/4885
US-20180282328-A1 NAPHTHYRIDINES AS INHIBITORS OF HPK1 NEK1, NEK5, NEK11 KDM5A 3056/4885JAK2 4501/4885JAK1 4271/4885
US-11034692-B1 Naphthyridines as inhibitors of HPK1 NEK1, NEK5, NEK11 KDM5A 3056/4885JAK2 4501/4885JAK1 4271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.